Trial Profile
Can tumor uptake of [18F]afatinib in NSCLC patients be quantified, and does [18F]afatinib uptake identify patients who will benefit from afatinib therapy ?
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Jul 2021
Price :
$35
*
At a glance
- Drugs Afatinib (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacokinetics; Proof of concept
- 07 Jul 2021 Status changed from planning to completed.
- 28 Jul 2015 New trial record